SQSP - CDTX PTGX and TAST among premarket gainers

2023-03-07 08:38:30 ET

• ThredUp ( TDUP ) +17% on Q4 earnings .
• Protagonist Therapeutics ( NASDAQ: PTGX ) +20% on positive topline results for Phase 2b FRONTIER 1 clinical trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis.
• BYND Cannasoft Enterprises ( NASDAQ: BCAN ) +18% .
• F-star Therapeutics ( NASDAQ: FSTX ) +15% on report sale to Sino Biopharma close to CFIUS approval.
• Legato Merger Corp. II ( NYSE: SLND ) +16% .
• Squarespace ( SQSP ) +14% on Q4 earnings .
• WW International ( WW ) +13% on buying telehealth provider Sequence .
• Unicycive Therapeutics ( NASDAQ: UNCY ) +12% .
• ATA Creativity Global ( NASDAQ: AACG ) +10% .
• Sea ( SE ) +10% on Q4 earnings .
• Ocular Therapeutix ( OCUL ) +9% on Q4 earnings .
• Nyxoah S.A. ( NASDAQ: NYXH ) +9% on achievement of key clinical and regulatory milestones .
• Carrols Restaurant Group ( NASDAQ: TAST ) +8% .
• DICK'S Sporting Goods ( DKS ) +6% on Q4 earnings .
• Cidara Therapeutics ( NASDAQ: CDTX ) +5% on entering into an underwriting agreement with Cantor Fitzgerald & Co.to issue and sell to Cantor 9,640,000 shares of the Company’s common stock.
• Precigen ( PGEN ) +5% on FY22 earnings .

For further details see: